Lp(a) Screening for Individuals at High ASCVD Risk

Adulting: Guidance for Transitioning Patients from Pediatric to Adult Lipid Clinics

The assumption is that patients can engage in self-care and can navigate the healthcare system, thus ensuring a smooth transition. This is an extended process…

Is There a Role for Aspirin in Prevention in 2022?

With recent guideline changes, it is common for clinicians to field questions regarding aspirin therapy. This article is intended to help clinicians apply an individualized…

Case Study: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obesity

Incretins are hormones secreted by intestinal cells in response to the ingestion of glucose and other nutrients. These hormones stimulate pancreatic β cells to secrete…

AHA Scientific Statement on Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) contributes to cardiovascular disease risk through dyslipidemia, insulin resistance, altered coagulation states, and increased inflammation. NAFLD occurs in greater than…

Polyphenols Protective Effects

Cardiometabolic disease is the concurrence of several disease states, including impaired glucose tolerance, hypertension, dyslipidemia, and visceral adiposity. These risk factors predispose patients to chronic…

A New Definition and Key Considerations for ASCVD Risk Reduction in the Statin Intolerant Patient

Times of New Technology: Therapies

The causal relationship between blood cholesterol and atherosclerotic cardiovascular disease (ASCVD) required many decades of research to establish and validate, and initial treatments focused on…